Researchers use expensive machinery to develop ways to harness DNA as a synthetic raw material to store large amounts of digital information outside of living cells.
But what if they could coerce living cells, such as large populations of bacteria, to use their own genomes as a biological hard drive that can record information scientists could tap anytime? That approach not only could open entirely new possibilities of data storage, it could also be engineered into an effective memory device able to create a chronological record of cells’ molecular experiences during development or under exposure to stresses or pathogens.
How to get smart, collaborative and go circular
If collaboration is king, governments, industry associations, communities and regions need a new armoury of policies and programs to advance talent and accelerate value-creating collaborations between companies.
Think UK with its open source and tax-friendly Patent Box legislation, a real boon to start-ups and SMEs. Or Scandinavian cluster programs with their matchmaking activities to foster innovation between SMEs so they can diversify into new markets, and their deep understanding of their industries’ dynamics. An example of such cluster mapping is the report Engineering the Green Economy on Northern Denmark’s win and energy cluster.
Good morning! Here’s the technology news you need to know this Wednesday.
1. Uber’s business is still growing despite months of bad news, scandals and turmoil. The company said its gross bookings for rides were up 10% from the previous quarter.
2. Analysts say that the “supercycle” that’s supposed to power iPhone 8 sales could just be a “cycle.” A note published by Deutsche Bank says that expectations for iPhone 8 sales are too high.
Meat and Livestock Australia is calling for applicants to its new GrowLab initiative to help agtech entrepreneurs commercialise beneficial technology for red meat industries.
GrowLab aims to develop selected innovations in areas such as robotics, animal health, remote sensing, food technologies and decision support tools.
Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequencing capacity in the world. Through this agreement, Novogene will purchase NextCollect™, Trovagene’s proprietary urine collection and nucleic acid preservation device for validation in the Chinese market.
Trovagene will sell Novogene the NextCollect urine collection and stabilization device, in addition to reagents and methods to extract cell-free DNA (cfDNA) from urine. Novogene plans to validate the urine DNA extraction methods at their facilities, including their lab in Tianjin, China, which is accredited by the College of American Pathologists (CAP).
FIT Biotech Oy (‘Company’) has received today a EUR 644,868 payment from its HIV collaborator, the European HIV Vaccine Alliance (EHVA). The payment was received as part of the contracted scheduled payments for manufacturing the Company’s investigational DNA-based HIV vaccine for a large multicenter Phase I/2 clinical trial planned to initiate later this year. EHVA is financed by the Horizon 2020 program of the European Commission.
FIT Biotech manufactures the investigational DNA-based HIV vaccine for EHVA in its own GMP production facility in Tampere, Finland, that is approved by the Finnish Medicines Agency (Fimea). This facility has the capacity to produce investigational drugs up to Phase 2 clinical trials, thus ensuring a rapid capability to introduce new DNA-based drug candidates to clinical trials.
Third positive data review by IDSMB follows completion of patient recruitment.
Paris and Boston, July 11th, 2017 – Neovacs (Euronext Growth: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it received a positive data review by the Independent Data and Safety Monitoring Board (IDSMB) for the ongoing Phase IIb Clinical Trial of IFNα Kinoid in lupus.
This is the third IDSMB data review of the ongoing Phase IIb clinical trial. The board reviewed the cumulative data, notably safety data from the study and informed the company that it has identified no safety concerns, and recommended the continuation of the study without any modifications. The trial is now fully enrolled with 178 patients randomized to receive either injection IFNα Kinoid vaccine or placebo.
Crop damage from a powerful herbicide is spreading across the southern U.S., spurring a flood of complaints to agricultural agencies and sowing division among farmers.
Hundreds of farms in Arkansas, Tennessee, Missouri and Mississippi have reported crops shriveled by dicamba. For farmers, lower crop yields due to herbicide damage could add to financial pressures after several years of low crop prices.
Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones.
Protein Sciences received approval from the US Food and Drug Administration (FDA) in October 2016 for their Flublok Quadrivalent Influenza Vaccine (QIV). Flublok is the only recombinant protein-based influenza vaccine approved by the FDA.
Canada has a competitive edge in a few key climate-friendly technologies including wind and solar power, energy efficient turbines, and waste management, according to a new Conference Board of Canada report.
‘Despite U.S. President Trump rolling back climate-friendly policies, the world is moving toward a cleaner, low-carbon economy and this represents a huge opportunity for Canadian companies,’ said Jacqueline Palladini, Senior Economist, The Conference Board of Canada. ‘Canadian innovators, investors, and producers can play a key role in helping the world’s businesses decrease their carbon footprint and lessen adverse environmental impacts by capitalizing on their global export strengths.’